Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News Diagnostics
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

Diagnostics

18 Oct 2022

Proposed placing, open offer and issue of convertible bonds

Diagnostics | Investors
18 Oct 2022

Proposed acquisition of Launch Diagnostics

Diagnostics | Investors
10 Jan 2022

Update on AffiDX® SARS-CoV-2 antigen lateral flow test and detection of the Omicron variant

Diagnostics | Investors
22 Dec 2021

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing

Diagnostics | Investors
15 Dec 2021

AffiDX® SARS-CoV-2 antigen lateral flow test detects the Omicron variant

Diagnostics | Investors
16 Nov 2021

New Paper: Clinical evaluation of AffiDX® SARS-CoV-2 Antigen Lateral Flow Test

Blogs | Diagnostics
02 Nov 2021

Update on UK Availability of AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test following Implementation of CTDA Regulations

Diagnostics | Investors
15 Sep 2021

Lateral Flow Assay Testing for COVID-19 – Tackling asymptomatic spread

Blogs | Diagnostics
04 Aug 2021

Update on AffiDX® SARS-CoV-2 Antigen Lateral Flow Test

Diagnostics | Investors
14 Jul 2021

Avacta’s Diagnostic Division Achieves ISO 13485 Certification

Diagnostics | Investors

Posts navigation

Older posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

FTI Consulting
200 Aldersgate
Aldersgate Street
London
EC1A 4HD

Email

Twitter | Linkedin

©2023 Avacta Life Sciences Limited. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok